Results 11 to 20 of about 7,902 (150)

SABR for oligometastatic renal cell carcinoma

open access: yesClinical and Translational Radiation Oncology
Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques.
Chang David   +8 more
doaj   +2 more sources

Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis

open access: yesRadiation Oncology, 2021
Background The purpose of this study was to compare the treatment efficacy and safety of re-irradiation (re-RT) using stereotactic ablative radiotherapy (SABR) and initial SABR for primary, recurrent lung cancer or metastatic lung tumor.
Tae Hoon Lee   +4 more
doaj   +1 more source

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

open access: yesCurrent Oncology, 2021
Background: Recent clinical trial results reported that stereotactic radiotherapy (SABR) may improve survival for patients with oligometastatic (OM) cancer. Given that these results come from a phase II trial, there remains considerable uncertainty about
Adam J. N. Raymakers   +3 more
doaj   +1 more source

Predicting pathological complete response (pCR) after stereotactic ablative radiation therapy (SABR) of lung cancer using quantitative dynamic [18F]FDG PET and CT perfusion: a prospective exploratory clinical study

open access: yesRadiation Oncology, 2021
Background Stereotactic ablative radiation therapy (SABR) is effective in treating inoperable stage I non-small cell lung cancer (NSCLC), but imaging assessment of response after SABR is difficult.
Dae-Myoung Yang   +12 more
doaj   +1 more source

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy

open access: yesRadiation Oncology, 2020
Background Stereotactic Ablative Radiotherapy (SABR) is an effective treatment that improves local control for many tumours. However, the role of SABR in gynecological cancers (GYN) has not been well-established.
E. Leung   +14 more
doaj   +1 more source

Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease

open access: yesFrontiers in Oncology, 2021
BackgroundIn certain malignancies, patients with oligometastatic disease benefit from radical ablative or surgical treatment. The SABR-COMET trial demonstrated a survival benefit for oligometastatic patients randomized to local stereotactic ablative ...
Dirk Mehrens   +11 more
doaj   +1 more source

Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma

open access: yesAdvances in Radiation Oncology, 2021
Purpose: Oligoprogression, defined as limited sites of progression on systemic therapy, in patients with metastatic renal cell carcinoma (mRCC) is not uncommon, possibly because of inter- and intratumoral heterogeneity.
Jonathan E. Schoenhals, BS   +18 more
doaj   +1 more source

Calibration of the chaotic interest rate model [PDF]

open access: yes, 2012
In this thesis we establish a relationship between the Potential Approach to interest rates and the Market Models. This relationship allows us to derive the dynamics of forward LIBOR rates and forward swap rates by modelling the state price density.
Tsujimoto, Tsunehiro
core   +2 more sources

SabR enhances nikkomycin production via regulating the transcriptional level of sanG, a pathway-specific regulatory gene in Streptomyces ansochromogenes

open access: yesBMC Microbiology, 2011
Background sabR is a pleiotropic regulatory gene which has been shown to positively regulate the nikkomycin biosynthesis and negatively affect the sporulation of Streptomyces ansochromogenes.
Liu Gang   +5 more
doaj   +1 more source

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study

open access: yesJournal for ImmunoTherapy of Cancer, 2023
Stereotactic ablative body radiation (SABR) delivers high rates of local control in early-stage non-small cell lung cancer (NSCLC); however, systemic immune effects are poorly understood.
Chen Hu   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy